Ryota Shibaki

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody

Ryota Shibaki, Shuji Murakami, Yuji Matsumoto et al. · Cancer Immunology Immunotherapy · 2019 · 88 citations · Full text

Medicine, Immunology, Oncology +17

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer

Hiroaki Akamatsu, Eriko Murakami, Jun Oyanagi et al. · The Oncologist · 2019 · 79 citations · Full text

Life Sciences, Immunology, Oncology +17

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with <scp>anti‐PD</scp>‐1 antibody

Shuji Murakami, Ryota Shibaki, Yuji Matsumoto et al. · Thoracic Cancer · 2020 · 55 citations · Full text

Medicine, Immunology, Oncology +17

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki et al. · CHEST Journal · 2022 · 40 citations

Medicine, Oncology, Pharmacology +12